No Products in the Cart
Biobanking Consent Document
Consent Document for Sample Storage and Additional Genetic Analyses
By choosing to have Wellness by Science™ store either your saliva sample or DNA extracted from your saliva, you are consenting to having Wellness by Science™ and its contractors access and analyze your stored sample, if they so choose, using the same or more advanced technologies (such as genetic sequencing), in a manner consistent with our Terms of Service and Privacy Statement. Unless we notify you otherwise, we may store your sample for a maximum of ten years. We may contact you in the event we need to re-analyze your sample. All of the same safeguards to any further use of your sample will be provided as in our Terms of Service and Privacy Statement.
Additional DNA Analyses of Stored Participant Samples
In addition, a subset of research participants may have their DNA reanalyzed using another technology, such as sequencing. The sequencing may focus on particular genes or regions, on the coding portions of the genome (also known as the exome), or on the whole genome. In addition, we may perform epigenomics studies on your sample. This is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The field is analogous to genomics and proteomics, which are the study of the genome and proteome of a cell. While the field of large-scale sequence analysis is still in its early stages, we can use methods that are being developed to compare sequence data with large public databases of genetic variation to identify and characterize functional genetic variation. The sample sizes needed for sequencing vary considerably depending on the type of study. To identify the causal mutation for a rare recessive disease may only require a nuclear family of four people. Identifying less penetrant rare modifiers of risk will likely require significantly more people. The studies with whole exome and whole genome data thus far have been mainly descriptive and better estimates of appropriate sample sizes will come as the methods for analysis are established. In the short term, sample sizes may mostly be limited by the cost and capacity of current high-throughput sequence providers.